Table 2. Demographics and oncological details of individual studies.
| First author, year of publication | No. of patients | Mean age (SD or range) | Male patients | Cancers | Stages (0/1/2/3/4) | Induction therapy (C/R/X) | Induction criteria |
|---|---|---|---|---|---|---|---|
| Bagan, 2009 (13) | 159 | 57 (±11) | 67% | NSCLC | –/30%/38%/30%/3% | 100%/–/– | N2, T3, T4, need for size reduction |
| Burfeind, 2005 (14) | 73 | 58 (11–78) | 60% | Any malignant etiology | –/33%/27%/25%/4% | 21%/–/79% | N2, hilar M1, T4, mediastinal invasion |
| Caso, 2018 (15) | 15 | 49 (±27) | 33% | Various tumors | 20%/33%/20%/20%/7% | 1C, others: NR | NR |
| Comacchio, 2019 (16) | 159 | 66 (36–84) | 79% | NSCLC | 2%/11%/73%/11%/3% | 76%/2%/22% | N2 |
| Gonzalez, 2013 (17) | 99 | 62 (29–83) | 76% | NSCLC | 3%/25%/37%/35%/– | 43%/–/57% | Potentially resecable T1–3N2M0 |
| Koryllos, 2020 (18) | 501 | 64 (NR) | 70% | Lung cancer | –/4%/42%/50%/4% | 30%/–/70% | N2, advanced mediastinal involvement |
| Milman, 2009 (19) | 64 | 60 (±10.6) | 73% | NSCLC | –/23%/27%/44%/6% | –/–/100% | NR |
| Gómez-Caro, 2012 (20) | 79 | 64 (38–83) | 89% | NSCLC | –/24%/53%/23%/– | –/–/100% | N2 |
| Veronesi, 2002 (22) | 55 | 63 (44–76) | 85% | Lung cancer | NR | 89%/–/11% | N2, T4, SCLC |
C/R/X, chemotherapy/radiotherapy/combined chemotherapy and radiotherapy. SD, standard deviation; NR, not reported; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.